Please login to the form below
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Thursday 9th July at 2pm BST / 9am EST
Choosing a price for a new product, and then justifying that price to payers, is a challenge for all pharmaceutical and biotechnology companies. This challenge becomes even more difficult if you are launching a product during a global economic recession. A panel of experts in pricing, chaired by our Senior Executive Advisor, Raf De Wilde, will discuss how best to navigate these pricing challenges and make sure you achieve the optimal price for your product.
Sign up for this webinar now here.
The panel for this webinar consists of:
- Anusha Patel, High Cost Medicines and Regional Homecare Lead Pharmacist for the East Midlands; Advisor to NICE and NHS England
- Bertrand Tardivel Former Head of Global Pricing at Takeda; founder of Freh
- Jaime Espin Former Member of the WHO Guideline Panel on Country Pharmaceutical Pricing Policies, and pricing advisor to the European Commission
Company Details
Valid Insight
+44 (0) 20 3750 9833
Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom
Latest content on this profile
- Webinar: How to develop an optimal value story for your product
- This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
- Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
- How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
- Using TRAVELLESS™ to provide tailored pharmaceutical training
- In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.
Valid Insight
- The vicious circle of pharmaceutical tendering
- Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
